Introduction 1
Melanoma is a potentially deadly cancer of transformed melanocytes, which are pigment-2 producing cells derived from embryonic neural crest. Early detection and treatment of melanoma 3 is critical because of high mortality associated with metastatic melanoma. The difficulty of treating 4 metastatic melanoma underscores the necessity of defining how this cancer initiates and the 5 urgency of developing new therapeutics (Lo and Fisher, 2014) . Encouragingly, chromatin 6 modifiers and other proteins that shape the epigenetic landscape offer promising novel therapeutic 7 targets that may expand the treatment repertoire beyond immunotherapy and MAPK-targeting 8 strategies (Tanaka et al., 2015; Badner et al., 2017) , and combat the ability of melanomas to evade 9 treatment due to the high mutational burden, heterogeneous mutations, and rapid evolution of these 10 tumors (Gallagher et al., 2014; Fontanals-Cirera et al., 2017) . 11
To effectively treat melanoma in its earliest stages requires a thorough understanding of 12 mechanisms that drive melanoma initiation. The transgenic BRAF V600E /p53 -/zebrafish has been 13 established as a powerful melanoma model that is highly reflective of the human disease and can 14 be utilized to study early stages of melanoma initiation (Patton et al., 2005) . In this model, the 15 human BRAF V600E oncogene is expressed under the control of the melanocyte-specific promoter of 16 the mitfa gene. Within BRAF V600E /p53 -/zebrafish, all melanocytes thus have the potential to 17 become melanoma, but only one to three melanomas typically develop from the many thousands 18 of melanocytes in any single fish, presenting an excellent model in which to study how cancer 19 initiates from a field of cancer-prone cells. 20
Recent work in zebrafish has demonstrated that reactivation of a neural crest program 21 (NCP) is an early step in melanoma initiation (Kaufman et al., 2016) . A single melanoma cell can 22 be visualized in live zebrafish by expression of the crestin:EGFP transgene (Kaufman et al., 2016) . 23 expression affects melanoma onset and maintenance, respectively (Kaufman et al., 2016; 1 Shakhova et al., 2012) . Likewise, overexpression of sox10 in melanocytes increases the rate of 2 melanoma onset in zebrafish (Kaufman et al., 2016) . Further demonstrating an NCP activation in 3 melanoma, regulatory elements near neural crest genes, such as sox10, are activated in melanoma 4 cells lines and NCCs, but not generally in other adult tissues or selected cancer cells lines 5 (Kaufman et al., 2016) . Importantly, this epigenetic phenomenon is conserved in human 6 melanomas (Kaufman et al., 2016) . 7
Since sox10 is critical to establish neural crest identity, the development of melanocytes, 8 and the maintenance and progression of melanoma (Kaufman et al., 2016; Shakhova et al., 2012; 9 Cronin et al., 2013) , epigenetic regulation of sox10 may be critical for re-establishing neural crest 10 identity in melanoma initiation. Therefore, identifying and functionally characterizing enhancer 11 elements that control sox10 expression during this oncogenic transition will broaden our 12 understanding of epigenetic changes that occur to trigger melanoma initiation and activation of an 13 NCP-like identity from within a cancerized field. 14 In this study, we functionally screen putative enhancers elements, identified as accessible 15 or "open" regions of chromatin using ATAC-Seq on zebrafish melanomas, near the sox10 gene for 16 transcriptional activating activity in embryonic neural crest as well as in melanoma tumors. This 17 screening approach allowed us to identify and focus initially on one 669 bp enhancer, termed 18 peak5, that is highly and specifically active in adult zebrafish melanoma. We further show that 19 peak5 is an active embryonic enhancer in a subset of the NCCs and a select population of Agduhr neurons in the central nervous system. We also identify a ~200 bp nucleotide sequence 21 centered within peak5 that is conserved between members of the fish Cyprinidae family and is 22 necessary and sufficient for neural crest activity. Furthermore, mutational analysis of a dimeric 23 SoxE binding site in the conserved core of peak5 uncovers transcription factor binding sites that 1 are necessary for robust peak5 neural crest activity. Together, these data enhance our 2 understanding of epigenetic changes that drive the re-emergence of neural crest identity in 3 melanoma and suggest a model wherein auto-regulation of sox10 in a feed-forward loop may 4 contribute to the formation of melanoma. 5 6
Results

7
Identification of putative sox10 enhancers 8
To identify putative regulatory elements surrounding the sox10 locus, ATAC-Seq was 9 performed on bulk melanoma tumors isolated from Tg(BRAF V600E ;crestin:EGFP);p53 -/zebrafish 10 ( Figure 1A) . ATAC-Seq on melanoma tumor cells showed consistent regions of open chromatin 11 and identified 11 regions of open chromatin around and within the sox10 locus, including a putative 12 sox10 minimal promoter encompassing exon 1 of sox10 (Figure 1B; Figure S1 ). These open 13 regions of chromatin were also consistent with ATAC-Seq peaks in zebrafish melanoma cell lines 14 (Kaufman et al., 2016) (Figure S1 ). To assess if these ATAC-Seq peaks are functional enhancers 15 in neural crest and melanoma cells, we performed in vivo reporter assays in Tg(BRAF V600E ); p53 -/-16 zebrafish embryos ( Figure 1C) . Putative non-intronic enhancers that were present in at least 4 out 17 of 5 tumor ATAC-Seq samples were cloned upstream of the mouse beta-globin basal promoter 18 driving EGFP (Tamplin et al., 2011) , within a Tol2 vector (394 from the Tol2 Kit) to enable mosaic 19 integration into the zebrafish genome. 20
Each putative enhancer construct was injected into single-cell Tg(BRAF V600E ); p53 -/-21 embryos. A crestin:mCh construct was also co-injected with each putative enhancer construct to 22 serve as a positive injection control and to co-label NCCs. Embryos were screened at 1 dpf for co-23 labeling of EGFP and mCh, indicating that the enhancer functions in the neural crest. Larva were 1 ranked as either "no expression," "weak expression," or "strong expression" for both EGFP and 2 mCh. "Strong expression" was characterized by 5 or more EGFP positive cells where as "weak 3 expression" was characterized by fewer than 5 EGFP positive cells. Nine out of eleven putative 4 enhancers drove EGFP expression in at least a subset of NCCs, as determined by cell shape, 5 location, and co-labeling with crestin:mCh (Figure S2) . One peak of interest, peak5, cloned as a 6 669 bp element (Figure S3) , exhibited particularly robust activity in NCCs (Figure 2A-B ). The 7 putative sox10 minimal promoter, cloned as a 351 bp element and potential positive control, 8 exhibited the most robust EGFP expression throughout the nervous system and in NCCs ( Figure  9 2C). A region of closed chromatin approximately 76 kb upstream of sox10, as determined by 10 ATAC-Seq, was also cloned upstream of betaglobin:EGFP as a negative control and did not drive 11 neural crest EGFP expression ( Figure 2D) . In subsequent analyses, we noted that this control 12 region also exhibits sequence similarity to another region on Chromosome 3 (Chr3: 45240516-13 45241216 ). An additional negative control (Negative Control A) cloned from a region 10.7 KB 14 upstream of the sox10 also exhibited minimal reporter activity ( Figure S2) . Collectively, ATAC-15 Seq analysis of zebrafish melanoma tumors reliably identifies transcriptional regulatory regions 16 near sox10 that function as enhancers with neural crest cell activity in transgenic reporter studies. 17
18
peak5 is active in embryonic neural crest and Kolmer-Agduhr neurons 19
Enhancer reporter constructs injected into zebrafish embryos are randomly integrated 20 throughout the genome, and thus subject to position effects (Udvadia and Linney, 2003) . In 21 addition to examining numerous F0 transgenic embryos for consistent spatial and temporal 22 expression as above, we further characterized the expression pattern of activity of peak5, a region 23 showing particularly robust neural crest activity in zebrafish embryos, by generating 6 independent 24 stable transgenic lines. To generate stable lines, F0 injected embryos were raised to maturity and 1 then outcrossed to Tg(BRAF V600E ); p53 -/zebrafish. Subsequent F1 embryos were then screened 2 for EGFP expression at 1 dpf. All 6 identified stable transgenic lines exhibited commonalities in 3 expression patterns, detailed below (Figure 3) . One stable line, peak5_115A exhibited EGFP 4 signal in muscle. Given that sox10 is not endogenously expressed in muscle, we reasoned that this 5 muscle activity was due to position effects, such as enhancer trapping, and as a result did not use 6 this line for subsequent analyses. 7
At 1 dpf, 4 out of 6 stable lines exhibited EGFP expression in pre-migratory NCCs dorsally 8 located on the posterior trunk ( Figure 3A , C, D, E). To confirm that peak5 is active in NCCs and 9 cells that would typically express sox10 we crossed Tg(peak5:betaglobin:EGFP) to either a 10 Tg(crestin:mCh) line (Figure 4A' ) or the previously published Tg(sox10(7.2):mRFP) line 11 (Kucenas et al., 2008) (Figure 4B') . Epifluoresence imaging of double transgenic embryos at 1 12 dpf showed most EGFP positive cells in the dorsal posterior region co-localize with mCh or mRFP 13 at 1 dpf ( Figure 4A-B') , illustrating that peak5 is active in NCCs. In addition to a subset of NCCs, 14 6 out 6 peak5 transgenic lines express EGFP within a subset of ventral Kolmer-Agdhur (KA) 15 neurons in the spinal cord, which contact cerebrospinal-fluid (Figure 3) , as identified by cell shape 16 and localization ( Figure S4 ). By 5 dpf, EGFP expression was consistently observed in KA neurons 17 across all lines, and in the heart in 3 out 6 stable lines (Figure 3) . 18 EGFP expression in adult fish was most prominent by epifluorescence in cells in the within 19 the tail, tip of the dorsal fin ( Figure 5A-C) , and peripheral nervous system, particularly observable 20 within the maxillary barbel, a sensory organ, which contains peripheral nerves and neural crest 21 derived Schwann cells ( Figure 5D) . Together, the similar expression patterns of EGFP between 22 different stable transgenic lines suggests that our peak5 transgenic zebrafish reflect endogenous 1 activity of peak5 in isolation. 2 3 peak5 is active in early melanoma patches and tumors 4
Given that peak5 is active in NCCs, we next asked if peak5 is an active enhancer in 5 melanoma. Excitingly, in every transgenic line assessed for tumor growth (Lines A, B, and C), 6
EGFP was expressed in nearly all melanoma tumors ( Figure 6 ; Table 4 ) (n = 55/59 EGFP+ 7 tumors in 51 animals). Not only is peak5 active in raised tumors, it is also active in small, unraised, 8 "preclinical" melanoma precursor lesions. Patches of EGFP positive cells, tracked over time, 9 drastically grew (Figure 7 ) (n = 9/15 EGFP+ patches tracked in 13 animals), similar to 10 crestin:EGFP positive patches (Kaufman et al., 2016) . The remaining 6/15 patches did not 11 obviously expand but remained at least stable over a 2-3 month time period observed. EGFP 12 localization in precursor lesions and tumors is particularly striking because EGFP is either 13 minimally or not detectably expressed by epifluorescence in adult melanocytes, relative to patches 14 and tumors, in the lines studied. Of note, differences in expression levels of EGFP in the body of 15 the fish may be due to differences in the copy number of the transgene. Overall, EGFP expression 16 in patches and tumors indicates that peak5 is an active enhancer in melanoma, and furthermore, 17 represents a sox10 regulatory element that is active during early stages of melanoma. To our 18 knowledge, this is the first time a single enhancer has been shown to be active specifically in early 19 melanoma patches and tumors in vivo. In addition to peak5, we also generated several stable lines 20 to assess activities of the sox10 minimal promoter, peak1, and peak8 in melanoma. As predicted, 21 the sox10 minimal promoter drove EGFP expression in melanoma patches and tumors across 6 22 stable lines (n = 38/46 EGFP+ tumors in 42 animals) (Figure S5A-C'; Table 4 ). Unlike peak5 23 transgenic lines, peak1 and peak8 stable lines expressed EGFP embryonically, but did not express 24 EGFP in nearly all melanoma tumors (n = 0/6 EGFP+ tumors in 6 peak1 transgenic animals from 1 1 stable line; n = 1/26 EGFP+ tumors in 25 peak8 transgenic animals from 3 independent stable 2 lines) (Figure S5D-G'; Table 4 ). These peak1 and peak8 data highlight the specificity of the 3 activity of peak5 from within the sox10 super-enhancer and demonstrate that not all sub-elements 4 are sufficient to drive EGFP expression in melanoma. These data also show that peak5 is an 5 enhancer upstream of the sox10 minimal promoter that is specifically active in melanoma, both in 6 precursor lesions and tumors. 7 8
A conserved sequence within peak5 is necessary for activity in NCCs and melanoma 9
We next asked if within peak5 there is a minimal sequence that is necessary for activity in 10 neural crest and melanoma. We hypothesized that any nucleotide conservation within peak5 11 between zebrafish and other animals would identify a more critical regulatory target region. 12
Nucleotide sequence conservation of enhancers between zebrafish and mammals is rare (Ritter et 13 al., 2010) ; accordingly, we did not observe any detectable colinear sequence conservation of peak5 14 in humans or mice. However, past sequence comparison of the zebrafish exomes to the exomic 15 sequence of its nearest relative, the common carp (Cyprinus carpio), revealed high conservation 16
of synteny and homologous coding sequences (Henkel et al., 2012) . Thus, we reasoned that 17 evolutionary important non-coding sequences may also be conserved. Aligning the nucleotide 18 sequence around the sox10 locus in both zebrafish and carp using Nucleotide BLAST revealed 19 discrete regions of conservation, including peaks 2, 4, 5, 8, 13 and the minimal promoter, as well 20 as most of the sox10 coding region (Figure 8A) . Interestingly, these conserved regions correspond 21 to enhancer assays that result in the most robust NCC expression ( Figure S2) . 22
Within peak5, we identified a 192 bp region that is conserved between carp and zebrafish, 23 as well as other selected members of the Cyprinidae family (Sinocyclocheilus grahami, 24
Pimephales promelas, Carassius auratus, and Oxygymnocypris stewartii) ( Figure 8B) . Regions 1 of conservation of peak5 between species other than carp were located on whole-genome shotgun 2 contigs through Nucleotide BLAST. Therefore, to verify that these regions of conservation are 3 indeed near sox10 in these other species, we aligned each identified scaffold to the zebrafish sox10 4 locus. We identified proximity to the sox10 locus and/or synteny with other putative sox10 5 regulatory regions for all other examined species except Pimephales promelas (Figure S6) . 6
To test if this peak5 conserved sequence is required for peak5 activity, we deleted the 7 sequence within the reporter assay plasmid containing the wild-type peak5 sequence ( Figure 8C) . 8
Interestingly, compared to full-length wild-type peak5 sequence, which exhibits activity in NCCs 9 and in KA neurons embryonically, embryos injected with the 192 bp conserved sequence deletion 10 construct (peak5D192:betaglobin:EGFP) exhibited diminished peak5 activity in NCCs, while 11 maintaining strong EGFP localization in KA neurons (Figure 8D-H' ). This suggests that this core 12 conserved sequence controls peak5 activity within NCCs. Injection of only the peak5 conserved 13 sequence (peak5_conserved:betaglobin:EGFP) resulted in labeling of only NCCs, albeit at weaker 14 levels compared to full-length peak5, demonstrating that the conserved sequence is sufficient for 15 peak5 activity in NCCs and is not sufficient for labeling of KA neurons (Figure 8D , 8I-J'). 16
In accordance with these mosaic analyses, embryos from peak5D192 stable transgenic lines 17 exhibit EGFP localization in KA neurons, but no clear localization in NCCs located in the dorsal 18 posterior region of the trunk (Figure 9A-A'; Figure S7 ). In contrast, NCCs in peak5_conserved 19 stable transgenic embryos are EGFP positive and KA neurons are not labeled ( Figure 9B-B' ; 20 Figure S7 ). In adult stable transgenic peak5_conserved zebrafish, cells within the maxillary barbel 21 are labeled, similar to wild-type peak5 stable lines ( Figure 9D) ; however, we did not observe 22 EGFP positive barbels in peak5D192 stable transgenic animals ( Figure 9C) . Furthermore, the 23 majority of tumors in adult peak5D192 stable transgenic animals are not EGFP positive (n = 21/23 1 EGFP-tumors in 22 animals from 3 different stable transgenic lines) (Figure 9E-F; Table 4 ). 2
These data suggest that the conserved sequence we identified is not only necessary for peak5 3 activity in a subset of NCCs, but also is necessary for robust peak5 activity in melanoma. 4 5 SoxE TFBS regulate peak5 activity in NCCs 6
We next asked which TFBS within this conserved region of peak5 are functionally 7 necessary for activity. Out of a list of predicted TFBS, some of which have roles in NCC 8 development, our attention was drawn to predicted dimeric SoxE binding sites ( Figure 10A) as it 9 was previously noted that such dimeric SoxE binding sites have been shown to exhibit functional 10 relevance in mouse Sox10 enhancers (Antonellis et al., 2008) . Furthermore, dimeric SOXE TFBS 11 with 3-5 bp spacers are enriched in human melanoma cell putative enhancers identified by DNase 12 hypersensitivity site mapping (Huang et al., 2015) . We therefore mutated both of these predicted 13 SoxE binding sites within the peak5 WT sequence to functionally test their necessity (Figure 10B Discussion 23 Melanoma initiating cells express aspects of a neural crest program that is maintained as a 1 tumor progresses (Kaufman et al., 2016) . One gene within the neural crest program, sox10, is a 2 critical regulator of NCC development and is also upregulated in both zebrafish and human 3 melanomas. Indeed, human melanomas immunostain positive for Sox10 in most cases, even more 4 often than the key melanocyte lineage regulator MITF (Clevenger et al., 2014; Ordóñez, 2014; 5 Willis et al., 2015) . Past work demonstrated that modulation of sox10 expression in melanocytes, 6 which normally lowly express sox10, affects melanoma onset rates (Clevenger et al., 2014; 7 Kaufman et al., 2016; Shakhova et al., 2012) , illustrating that sox10 plays a key role during 8 melanoma initiation. Therefore, deciphering the epigenetic regulation of sox10 may elucidate 9 earlier mechanisms of melanoma initiation that drive NCP activation. Ongoing studies continue to 10 decipher the embryonic function of sox10 in zebrafish (Chong-Morrison et al., 2018; Dutton et al., 11 2001; Kelsh and Eisen, 2000) , but to date, regulation of sox10 expression in melanoma is poorly 12 understood. In this study, we screened individual putative sox10 regulatory elements for activity 13 within NCCs and melanoma in zebrafish. From this analysis, we identified peak5, an enhancer that 14 is active in embryonic neural crest and melanoma, including precursor lesions. 15
Using ATAC-Seq data generated from zebrafish melanoma tumors, we identified putative 16
regulatory regions of open chromatin surrounding and within the sox10 locus. Injection of reporter 17 constructs harboring these putative enhancers into embryos revealed that 9 out of 11 displayed 18 some level of activity within NCCs, as compared to injected negative controls, indicating their 19 potential as active enhancers in melanoma. Generation of multiple stable lines revealed that peak5, 20 a 669 bp sequence from 22.8 kb upstream of the sox10 transcriptional start site, is active 21 embryonically in a subset of NCCs and KA neurons. In zebrafish adults, peak5 is at most 22 minimally active in melanocytes in in vivo EGFP reporter assays, and is highly active in melanoma 23 patches and tumors. Furthermore, we identified a region within peak5 that is conserved between 1 members of the Cyprinidae family and mediates the NCC activity of peak5. Within this conserved 2 region, dimeric SoxE binding sites are critically necessary for peak5 activity within the neural 3 crest. Together, peak5 serves as a proxy enhancer to understand how transcriptional regulation of 4 sox10 and potentially other melanoma enriched genes influences melanoma initiation. 5
The identification of crestin as an early marker of melanoma provided a live marker of the 6 earliest detectable events of melanoma initiation and confirmed that the NCP activation is an early 7 step in the process (Kaufman et al., 2016) . This study expands upon this knowledge by identifying 8 a regulatory element that can also be utilized as an in vivo specific reporter of melanoma initiation. 9
Importantly, unlike crestin, sox10 is conserved across all vertebrate species; therefore, identifying 10 sox10 enhancers that are active in melanoma in zebrafish could lead to the identification of human 11 SOX10 enhancers that influence melanoma onset. While we were unable to identify stretches of 12 colinear conserved sequence between the zebrafish and human/mouse upstream regions of SOX10, 13 predicting the regulatory function of enhancers based on sequence conservation alone is often not 14 possible, such as in the case of RET enhancer elements, which function faithfully between human 15 and zebrafish in reporter assays, but are not conserved in an obvious way at the primary nucleotide 16 level (Fisher, 2006) . 17
Further, we were intrigued to find that while zebrafish sox10 enhancers are not conserved 18 in a colinear sequence with potential human SOX10 enhancers, several zebrafish enhancers are 19 conserved by nucleotide sequence between members of the Cyprinidae family. Conservation of 20 peaks 2, 4, 5, 8, 13 and the sox10 minimal promoter between zebrafish and carp suggest an 21 evolutionary pressure to maintain these regulatory sequences. Interestingly, the highest region of 22 conservation for each peak is oriented near the center of the ATAC-Seq peak, including peak5. As 23 the conserved region of peak5 controls activity in NCCs, but not activity in KA neurons, regions 1 of conservation in peaks 2, 4, 8, and 13 may represent core sequences that control NCC activity of 2 the enhancer. Future work to dissect the role of these core conserved enhancers in NCC 3 development and melanoma will test this hypothesis. 4
This region of high conservation within peak5 also leads to the hypothesis that the key 5 TFBS controlling peak5 activity in NCCs and melanoma are also conserved. Identification of SoxE 6 dimeric binding sites points toward potential transcription factors, most notably Sox10, that may 7 bind and activate peak5. Similar to deletion of the conserved sequence within the context of full-8 length peak5, mutation of both SoxE TFBS lessens peak5 activity in NCC, but does not affect 9 peak5 activity within KA neurons. Therefore, members of the SoxE family (Sox10, Sox9, and 10 Sox8) are candidate transcription factors that may bind and activate peak5. Dimeric SOXE binding 11 sites are overrepresented in human melanoma cells in regions of open chromatin (Huang et al., 12 2015) and have also been observed near promoters of genes regulated by Sox10 (Mollaaghababa 13 and Pavan, 2003) , suggesting that Sox10 may bind the dimeric sites in peak5. Mutation of the 14 dimerization domain within Sox10 in mice also causes defects in melanocyte development, 15 underscoring the importance of dimeric Sox10 binding (Schreiner et al., 2007) . 16
Interestingly, dimeric SoxE sites have also been shown to be necessary for activity of two 17 mouse Sox10 enhancers, MCS4 and MCS7 (Antonellis et al., 2008) . Since zebrafish sox10 18 enhancers are not conserved by sequence with mouse Sox10 enhancers, it will be interesting to test 19 if either mouse MCS4 or MCS7 Sox10 enhancers have overlapping embryonic and adult activity 20 patterns with peak5 in zebrafish. Moreover, examining the other functional TFBS present in peak5 21 in zebrafish may help predict and identify a peak5-equvialent enhancer in humans that is depend 22 on the same or similar complement of TFBS. 23
One caveat of determining the functionality of a putative enhancer is the potential to 1 identify false positives. In zebrafish, random genome integration of enhancers using the Tol2 2 system can result in enhancer trapping (Udvadia and Linney, 2003) . Thus, we generated multiple 3 stable lines for peak5, which exhibited similar expression patterns, suggesting that our lines reflect 4 endogenous spatial and temporal activity of peak5 embryonically and in melanoma. Variations 5 amongst transgene integration site in different stable lines leading to subtle position effects in 6 addition to genomic instability in melanoma tumors, may also explain why we occasionally 7 observe EGFP negative tumors in stable lines that predominately express EGFP in tumors (peak5 8 n = 4/59 EGFP negative tumors) and a small number of EGFP positive late-stage tumors in peak8 9 (n = 1/26) and peak5D192 (n = 2/23) stable lines. 10
Finally, we propose a model by which peak5 contributes to increased sox10 expression 11 regulation in melanoma initiation and progression (Figure 11 ). In this model, the peak5 region is 12 open and enhances sox10 expression in early melanoma precursor lesions and, through a feed-13 forward mechanism, autoregulates increasing sox10 expression by binding at the dimeric SoxE 14 sites in peak5. Again, while stretches of conserved, noncoding DNA are most often not readily 15 identifiable by comparison between humans/mouse and zebrafish, the presence of such dimeric 16 SoxE sites in bona fide murine NCC enhancers (Antonellis et al., 2008) and putative human 17 melanoma enhancers (Huang et al., 2015) is consistent with this potentially being a general 18 mechanisms by which Sox10 target genes are upregulated in melanoma. Given that peak5 is not 19 active in all cells that express sox10 during embryogenesis, other sox10 enhancers likely also 20 contribute to sox10 regulation during melanoma initiation. Together, developmentally incorrect 21 re-activation of sox10 enhancers in zebrafish and human melanomas suggests that understanding 22 the activity and contribution of individual enhancers within this locus will illuminate earlier 23 initiating steps of melanoma. This study identifies one of these enhancers, peak5, that is active 1 embryonically and in melanoma, and lays the groundwork to further dissect the role of other sox10 2 enhancers in zebrafish and higher vertebrates in melanoma initiation. 3 or groups, and embryos were raised in egg water (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 8 0.33 mM MgSO4) at 28.5˚C. Larvae were staged at days post fertilization (dpf) and adults were 9 staged at months post fertilization (mpf). The following strains of transgenic zebrafish were used 10 in this study: AB*, Tg(BRAF V600E /p53 -/-/crestin:EGFP) (Kaufman et al., 2016) , 11
Methods and Materials
Tg(BRAF V600E );p53 -/- (Patton et al., 2005) , Tg(sox10(7.2):mRFP) (Kucenas et al., 2008) , 12 Isolation of Bulk Tumors 17 Following humane euthanasia, grossly visible bulk melanoma tumors from Tg(BRAF V600E / 18 crestin:EGFP);p53 -/zebrafish were excised with a razor, manually sheared, and incubated in fresh 19 0.9X PBS with 2.5 mg/mL Liberase for up to 30 minutes to dissociate cells. Fetal bovine serum 20 addition terminated the digestion, and the cells were passed through a 40 mm filter. Cells were 21 centrifuged at 2000 x g for 5 minutes at 4 o C. Supernatant was removed and the cells were 22 resuspended in 500 µL of 0.9X PBS and kept on ice. 23 1 ATAC-Seq 2 50,000 cells per sample underwent tagmentation reaction with Nextera Tn5 transposase using the 3 Illumina Nextera kit and purified with a Qiagen MinElute reaction kit (Buenrostro et al., 2015) . 4
The DNA was then PCR amplified for 9 cycles to add indexing primers. SPRI AMPure beads 5 enriched for fragments under ~600 bp. The DNA was cycled again with the 9-cycle protocol, 6 followed by cleanup with SPRI AMPure beads. The DNA was quantified with a Qubit DNA High 7 Sensitivity assay and analyzed for quality and size distribution on an Agilent TapeStation with a 8
High Sensitivity D5000 ScreenTape. Samples were pooled for a 10 nM final overall 9 concentration. Sequencing was performed with an Illumina HiSeq 2500 system with 2 x 50 bp 10 read length by the Washington University in St. Louis School of Medicine Genome Technology 11 Access Center. 12
13
ATAC-Seq Data Analysis 14
Reads were demultiplexed then trimmed with Cutadapt (adaptor sequence 5'-15 CTGTCTCTTATACACATCT-3' for both reads) and checked with FastQC to ensure quality. The 16 reads were aligned to the GRCz10/danRer10 genome using BWA-MEM and sorted using 17
SAMtools. Duplicate reads removed with Picard tools using the following parameters: 18
ASSUME_SORTED=true, VALIDATION_STRINGENCY=LENIENT. The files were indexed 19 with SAMtools then filtered for high quality alignments using the following parameters: -f 3, -F 20 4, -F 8, -F 256, -F 1024, -F 2048, -q 30. MACS2 was then used to identify peaks with the callpeak 21 command with parameters -g 1.4e9, -q 0.05, --nomodel, --shift -100, --extsize 200. Differential 22 peak accessibility was assessed with the MACS2 bdgdiff function. HOMER was then used to 23 annotate the peaks (annotatePeaks.pl) and identify enriched transcription factor motifs using 1 findMotifsGenome.pl (-size 200, -mask parameters) . 2 3
Cloning putative enhancers 4
All putative enhancer elements except for peak13 were PCR amplified from genomic DNA from 5 AB* zebrafish larvae or Tg(BRAF V600E );p53 -/larvae with high-fidelity DNA polymerases. peak13 6 was amplified from BAC CHORI-211:212I14 (a gift from the Johnson Lab). Genomic locations 7 for each putative enhancer in the Zv10 build of the zebrafish genome are listed in Table 1 and 8 primers used to amplify each sequence and total cloned sizes of each element are listed in Table  9 2. PCR amplified enhancer elements were cloned into pENTR5' vectors (ThermoFisher). Anytime 10 Phusion (NEB) was utilized to amplify a putative enhancer, adenines were added to the end of the 11 PCR product using Taq polymerase (Promega) before performing a TOPO reaction. Using 12 plasmids from the Tol2 kit, all putative enhancers were placed upstream of a basal promoter, 13 mouse beta-globin (Tamplin et al., 2011) via Gateway LR reactions with the following 14 combination of Gateway vectors: p5E-enhancer, pME-betaglobin:EGFP, p3E-polyA, and 15 pDestTol2pA. To generate a sox10 minimal promoter plasmid, a sox10 minimal promoter was 16 PCR amplified from genomic DNA from AB* larvae with primers (Table 1 and 2) containing 17 overlapping nucleotides to sequences on either side of the AgeI site in pENTR-EGFP2 (Addgene 18 #22450), similarly described in (Quillien et al., 2017) . The PCR product was then cloned into 19 pENTR-EGFP2 and digested with AgeI, through a Gibson Assembly reaction using an in-house 20 sox10minimalpromoter:EGFP was then used in a Gateway LR reaction with p5E-MCS, p3E-23 polyA, and pTol2Destp2A to generate the final reporter construct. All PCR amplified sequences 24 were Sanger sequenced by Genewiz. The list of plasmids used in this study can be found in Table  1 3. The conserved peak5 sequence was PCR amplified from the previously cloned peak5 sequence, 2 cloned into a pENTR5' vector, and placed upstream of betaglobin:EGFP through a Gateway 3 reaction, as described above. 4 5
Screening putative enhancers and generation of transgenic zebrafish lines 6
One cell stage Tg(BRAF V600E );p53 -/embryos were injected with 20 ng/µL of an enhancer reporter 7 plasmid in addition to 15 ng/µL of crestin:mch, and 20 ng/µL of Tol2 transposase mRNA. 1 dpf 8 larvae were screened for EGFP and mCh localization in the neural crest on a stereomicroscope. 9
Embryos were scored as "strong expression" if 5 or more cells were EGFP and mCh positive. 10 Three technical and biological replicates of injections were performed for each putative enhancer. 11
At least 30 embryos scored as positive from each replicate were raised to adulthood. Founders 12 were identified by out-crossing F0 adults, and progeny were screened from 1 dpf -5 dpf for EGFP 13 localization and subsequently raised to adulthood and screened for EGFP expression in melanoma 14 patches and tumors ( Table 4) . 15
16
Imaging 17 For live-imaging, larvae were anesthetized in Tricaine, embedded in 0.8% agarose, and imaged 18 with a Nikon SMZ18 fluorescent dissecting microscope. For imaging adults, fish were 19 anesthetized in Tricaine and imaged with a Nikon SMZ18 fluorescent dissecting microscope. 20
Images were processed with Photoshop and ImageJ. The Photomerge function in Photoshop was 21 used to stitch together tiled images of adult zebrafish. 22
23
Evolutionary conserved sequence identification 24
To generate the Dot-Matrix view, sequences surrounding the sox10 locus in both zebrafish 1 (Chromosome 3: 1976387-2026723, danRer10 ) and carp (scaffold: LG6, Chromosome 6: 2 16126287-16150639), were aligned with optimization for more dissimilar sequences in BLAST 3 (http://blast.ncbi.nlm.nih.gov). BLAST with optimization for more dissimilar sequences with 4 discontiguous megablast was also used to compare the zebrafish peak5 sequence to selected 5 members of the Cyprinidae family ( Table 5 ). The nucleotide collection or whole-genome shotgun 6 contigs databases were chosen as the search set. The most conserved regions of peak5 nucleotide 7 sequences from each species were then aligned with M-Coffee 8 (http://tcoffee.crg.cat/apps/tcoffee/do:mcoffee). The fasta_aln file was downloaded and Boxshade 9 (https://embnet.vital-it.ch/software/BOX_form.html) was then used to shade the alignment using 10 RTF_new as the output format and "other" as the input sequence format. TFBS predictions were 11 identified with FIMO (http://meme-suite.org/tools/fimo) using the JASPAR core 2016 vertebrate 12 list.
SoxE dimeric binding sites were predicted with JASPAR 13 (http://jaspar.genereg.net/search?q=&collection=CORE&tax_group=vertebrates), searching 14 explicitly for Sox10 motifs using an 80% relative profile score threshold. 15
16
Plasmid Mutagenesis and Deletion Analysis 17
The Q5 Site-Directed Mutagenesis Kit (NEB) was used according to the manufacturer's 18 instructions to either delete the peak5 conserved 192 base pair sequence or mutate SoxE binding 19 sites. The correct deletion or mutations were confirmed through Sanger Sequencing at Genewiz. 20 20 ng/µL of peak5 full-length wild type, peak5∆192, or peak5 full-length SoxE site mutated 21 plasmids were co-injected with 15 ng/µL of crestin:mch and 20 ng/µL of Tol2 transposase mRNA 22 into embryos derived from a Tg(BRAF V600E );p53 -/in-cross. Only embryos that expressed mCh, 23 ensuring successful injection, were scored on 1 dpf for expression of EGFP. EGFP+ embryos that 24 had identifiable cell type labeling were categorized into the following cell-localization categories: 1 neural crest, KA neurons, both the neural crest and KA neurons, or ectopic. The scorer was blinded 2 to treatment groups when scoring. Three technical and biological replicates were performed for 3 the conserved deletion experiment and two technical and biological replicates were performed for 4 the SoxE TFBS mutation experiment. Stable lines were identified and characterized as described 5 above ( Table 4) premigratory NCCs and strong localization in KA neurons. By 3 dpf and 5 dpf, EGFP localization is primarily within KA neurons and the heart. C) Line C mainly exhibits EGFP localization in KA neurons at 1 dpf, 2 dpf, and 3 dpf. D) In Line 129B, NCCs, KA neurons, and cells in the cranial CNS are strongly labeled with EGFP at 1 dpf. Labeling of some NCCs is maintained at 2 dpf, and by 5 dpf EGFP is primarily localized within KA neurons and parts of the head. E) Line 219K exhibits EGFP localization in some premigratory NCCs, KA neurons, and the heart at 1 dpf. At 5 dpf, EGFP is mainly localized in KA neurons and the heart. F) Line 115A displays signs of ectopic EGFP expression. At 1 dpf, EGFP localization is mainly visible in KA neurons and the heart. By 2 dpf, EGFP is also localized in the muscles, which is more prominent at 5 dpf. KA neurons and the heart are also labeled at 2 dpf and 5 dpf. 
